| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a933a0dd561e3e50b278738704d5c6e6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-00 |
| filingDate |
2006-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e60903d2a56c5af64059b753c8bf1a7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2dd46866e6b199c5a5b54996ad672e4e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f01ea94cac382703cef522ebb845417
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f2d831b3adc02b2eec9fae466db79eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3bc8720083b0210aa95e1fc512be333
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9ac6fa34c8fa52aa34d8c7ae31bdb02 |
| publicationDate |
2008-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1933869-A2 |
| titleOfInvention |
Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease |
| abstract |
Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8617552-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7807155-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10344084-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9765140-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8119131-B2 |
| priorityDate |
2005-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |